-
Philip Tagari
VP of Research at Amgen Inc.
Learn morePhilip Tagari
VP of Research at Amgen Inc.
Philip Tagari is Vice President of Research (Therapeutic Discovery) at Amgen Inc., the world’s largest independent biotechnology company. His global laboratories are responsible for multi-modality platforms resulting in the successful progression of over 30 innovative molecules into clinical development in recent years. Before joining Amgen in 1998, he was a Research Fellow at Merck Frosst (Canada) Inc., where he contributed to several eicosanoid and inflammatory biology programs. Tagari is an active member of Amgen Ventures and has participated in numerous research collaborations. He is also Board Chair for Amgen Biopharmaceutical Research and Development (Shanghai) Co., Ltd., a board member of MATWIN (Maturation & Accelerating Translation With Industry) in France, and a Director of CQDM (Consortium Quebecois sur la Decouverte du Medicament; Quebec Consortium for Drug Discovery). Tagari holds a Master’s in Natural Sciences from Gonville & Caius College, Cambridge University (UK).
-
Philip Larsen
SVP and Global Head of Research at Bayer Pharmaceuticals
Learn morePhilip Larsen
SVP and Global Head of Research at Bayer Pharmaceuticals
“The frontier of innovation for the life science industry is defined by those who can bring sense to the overwhelming amount of data points generated every day. I am impressed by BenchSci’s ability and vision to do exactly that as it will not only improve research efficiencies but also bring the scientific community novel insights to complex biologic systems.”
Philip Larsen is the Senior Vice President and Global Head of Research at Bayer Pharmaceuticals. He joined Bayer in July 2019, before which he was Chief Scientific Officer at Grünenthal. Before that, he served as Chief Scientific Officer, German Hub at Sanofi. Larsen has 27 years of pharmaceutical and biotechnology industry experience focusing on diabetes and obesity, with 20 years of leading research divisions. After a few years of work at NovoNordisk and Zealand Pharma, he cofounded the Danish biotechnology company Rheoscience in 2001. In 2008, he took up a position as Chief Scientific Officer for Diabetes Research at Eli Lilly, Indianapolis, USA, before returning to Europe as Vice President for Early Clinical Development in CVM at AstraZeneca. He holds an M.D. and a Ph.D. in neuroendocrinology, both from the University of Copenhagen.
-
Steve Hitchcock
Chief Scientific Officer at Takeda Pharmaceuticals
Learn moreSteve Hitchcock
Chief Scientific Officer at Takeda Pharmaceuticals
“I’m delighted to be able to work with the outstanding team at BenchSci who are broadly applying cutting edge AI technologies to accelerate the discovery of new therapeutics.”
Steve Hitchcock is the Chief Scientific Officer at Takeda Pharmaceuticals. He is responsible for the global research organization at Takeda across the four therapeutic areas of neuroscience, oncology, gastrointestinal diseases, and rare diseases. Hitchcock joined Takeda as part of their acquisition of Envoy Therapeutics, where he was the Chief Scientist and Senior Vice President of Drug Discovery. Before Takeda, he served in senior leadership positions in the research organizations at both Eli Lilly and Amgen. He also served as an adjunct professor in the Department of Molecular Therapeutics at Scripps Florida, a division of The Scripps Research Institute. Hitchcock completed a NATO postdoctoral fellowship at Yale University and holds a Ph.D. in organic chemistry from the University of Nottingham (U.K.).
Culture and technology advisors
-
Jean-Michel Lemieux
Former CTO/VPE Shopify & Atlassian
Learn moreJean-Michel Lemieux
Former CTO/VPE Shopify & Atlassian
“I’m excited to be helping BenchSci scale and grow their team and technology platform. We’ve learned from the pandemic that it’s critical to invest in technology that helps speed up our scientists as they research and test new health innovations.”
Jean-Michel Lemieux has worked in tech for almost 30 years, building software and then building teams and companies. Educated at the University of Ottawa, he was a founding member on the Eclipse platform and open-source teams. He then led and grew the engineering organizations at Atlassian and Shopify and prepared both companies to scale and IPO. He is a published author, investor, and advisor and has a passion for community and education, co-founding Canadian Tech @ Scale which brings together tech leaders from across Canada, and DevDegree.ca, an accredited work-integrated computer science degree.
-
Richard Zemel
Professor of Computer Science at the University of Toronto
Learn moreRichard Zemel
Professor of Computer Science at the University of Toronto
Richard Zemel is a Professor of Computer Science at the University of Toronto, where he has been a faculty member since 2000. Before that, he was an Assistant Professor in Computer Science and Psychology at the University of Arizona and a Postdoctoral Fellow at both the Salk Institute and Carnegie Mellon University. His research contributions include foundational work on systems that learn useful representations of data without any supervision, methods for learning to rank and recommend items, and machine learning systems for automatic captioning and answering questions regarding images. Zemel holds B.Sc. degrees in history and science from Harvard University and a Ph.D. in computer science from the University of Toronto. He is also a Fellow of the Canadian Institute for Advanced Research and serves on the Executive Board of the Neural Information Processing Society, which organizes the premier international machine learning conference.
-
Milind Kamkolkar
Chief Digital & Data Officer at Cellarity
Learn moreMilind Kamkolkar
Chief Digital & Data Officer at Cellarity
Milind Kamkolkar is the Chief Digital & Data Officer at Cellarity. There, he leads the implementation of machine learning science in a digital biology landscape to explore new clinical hypotheses that can alter cell behaviors. Milind joined Cellarity from Sanofi, where he was the first Enterprise Chief Data Officer in the pharmaceutical industry. His focus at Sanofi was transforming the organization from a data-generation organization into a data-driven organization to empower patients and increase Sanofi’s value to customers. He drew his approach from his tenure at Novartis, where he was the Global Head of Data Science and AI in Digital Medicines. Kamkolkar has served as a board advisor and mentor to numerous startups, founders, and VC firms focused on entering the life science space through digital, data, or AI. He holds a B.Sc. from the University of Sydney and an M.S. from Thomas Jefferson University.
-
Jessica Neal
Venture Partner at TCV
Learn moreJessica Neal
Venture Partner at TCV
“BenchSci plays an important role in curating and contextualizing healthcare data to increase productivity in the preclinical research process, and I look forward to supporting Liran and his team as they scale the business and team.”
Jessica Neal is a Venture Partner with TCV, working closely with the investment team and portfolio companies. TCV co-led BenchSci’s Series C $63 million funding round with Inovia Capital earlier this year. An experienced operational leader who has built teams and cultures at scale, Neal was most recently the Chief Talent Officer at Netflix. She spent over 11 years there, helping to scale the team and culture to pivot from shipping physical DVDs to streaming content globally. Previously, Neal was the Chief People Officer for Scopely and the Head of People for Coursera.